Wedbush Has Bearish Estimate for ARTV FY2024 Earnings

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) – Research analysts at Wedbush dropped their FY2024 earnings estimates for shares of Artiva Biotherapeutics in a research note issued to investors on Wednesday, November 13th. Wedbush analyst D. Nierengarten now forecasts that the company will earn ($5.08) per share for the year, down from their previous estimate of ($4.55). Wedbush has a “Outperform” rating and a $18.00 price target on the stock. The consensus estimate for Artiva Biotherapeutics’ current full-year earnings is ($4.60) per share. Wedbush also issued estimates for Artiva Biotherapeutics’ FY2025 earnings at ($2.61) EPS, FY2026 earnings at ($2.76) EPS and FY2027 earnings at ($2.91) EPS.

Other equities analysts have also issued reports about the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $23.00 target price on shares of Artiva Biotherapeutics in a report on Wednesday. Cantor Fitzgerald began coverage on Artiva Biotherapeutics in a research report on Tuesday, August 13th. They set an “overweight” rating and a $23.00 target price on the stock. TD Cowen began coverage on Artiva Biotherapeutics in a report on Tuesday, August 13th. They issued a “buy” rating for the company. Finally, Jefferies Financial Group assumed coverage on Artiva Biotherapeutics in a research report on Tuesday, August 13th. They issued a “buy” rating and a $21.00 price objective for the company. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Artiva Biotherapeutics currently has a consensus rating of “Buy” and an average price target of $21.25.

Artiva Biotherapeutics Trading Down 4.3 %

Artiva Biotherapeutics stock opened at $10.06 on Friday. Artiva Biotherapeutics has a 52 week low of $9.68 and a 52 week high of $17.31. The business’s 50-day moving average is $12.53.

Artiva Biotherapeutics (NASDAQ:ARTV) last posted its earnings results on Tuesday, November 12th. The company reported ($0.92) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.24).

Hedge Funds Weigh In On Artiva Biotherapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC purchased a new stake in shares of Artiva Biotherapeutics during the 3rd quarter valued at approximately $4,774,000. Barclays PLC acquired a new stake in Artiva Biotherapeutics in the 3rd quarter valued at approximately $304,000. State Street Corp acquired a new stake in shares of Artiva Biotherapeutics in the third quarter valued at $1,337,000. BNP Paribas Financial Markets purchased a new stake in Artiva Biotherapeutics during the third quarter worth about $42,000. Finally, Charles Schwab Investment Management Inc. acquired a new position in shares of Artiva Biotherapeutics in the third quarter valued at approximately $623,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.